Heinz Feldmann

Oct 10, 2024 | nature.com | Andrea Marzi |Heinz Feldmann

AbstractNowadays, filovirus vaccine development may be seen as a paradigm for our response capabilities to emerging and re-emerging infectious diseases. Specifically, the West African Ebola virus disease (EVD) epidemic accelerated countermeasure licensure for several vaccine and therapeutic products. Those products have been successfully used to control EVD outbreaks in Central Africa over the past years. This positive development, however, has not yet reached beyond EVD.

Mar 27, 2024 | nature.com | Vanessa Monteil |Shane Wright |Sofia Appelberg |Hyesoo Kwon |Ioannis Pittarokoilis |Georg Michlits | +11 more

AbstractClimate change and population densities accelerated transmission of highly pathogenic viruses to humans, including the Crimean–Congo haemorrhagic fever virus (CCHFV). Here we report that the Low Density Lipoprotein Receptor (LDLR) is a critical receptor for CCHFV cell entry, playing a vital role in CCHFV infection in cell culture and blood vessel organoids.

Oct 25, 2023 | nature.com | Vanessa Monteil |Hyesoo Kwon |Cristiano Salata |Gustav Jönsson |Sofia Appelberg |Astrid Hagelkrüys | +7 more

AbstractMarburg and Ebola filoviruses are two of the deadliest infectious agents and several outbreaks have occurred in the last decades. Although several receptors and co-receptors have been reported for Ebola virus, key host factors remain to be elucidated. In this study, using a haploid cell screening platform, we identify the guanine nucleotide exchange factor CCZ1 as a key host factor in the early stage of filovirus replication.

Mar 14, 2023 | nature.com | David W Hawman |Heinz Feldmann

AbstractCrimean–Congo haemorrhagic fever (CCHF) is a severe tick-borne illness with a wide geographical distribution and case fatality rates of 30% or higher. Caused by infection with the CCHF virus (CCHFV), cases are reported throughout Africa, the Middle East, Asia and southern and eastern Europe. The expanding range of the Hyalomma tick vector is placing new populations at risk for CCHF, and no licensed vaccines or specific antivirals exist to treat CCHF.